Comparative Pharmacology
Head-to-head clinical analysis: SODIUM IODIDE I 131 versus SPECTAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM IODIDE I 131 versus SPECTAMINE.
SODIUM IODIDE I 131 vs SPECTAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium iodide I 131 is a radioactive isotope that emits beta particles and gamma rays. It is taken up by the thyroid gland via the sodium-iodide symporter and incorporated into thyroid hormones. The beta radiation causes local destruction of thyroid tissue, reducing hormone production and treating hyperthyroidism or thyroid cancer.
SPECTAMINE (iofetamine I-123) is a radiopharmaceutical that crosses the blood-brain barrier and localizes in the brain proportional to regional cerebral blood flow. It binds to striatal dopamine transporters (DAT) and is used as a marker for dopamine transporter density.
For thyroid ablation or therapy of thyrotoxicosis: 100-200 mCi (3.7-7.4 GBq) orally as a single dose. For diagnostic imaging: 5-10 μCi (0.185-0.37 MBq) orally.
SPECTAMINE (technetium Tc-99m exametazime) is administered intravenously. For brain imaging, the recommended adult dose is 10-20 mCi (370-740 MBq). For white blood cell labeling, the dose is 10-20 mCi (370-740 MBq) after labeling autologous leukocytes.
None Documented
None Documented
Physical half-life: 8.02 days. Effective half-life in euthyroid patients: ~5-7 days, but reduced to ~3-5 days in hyperthyroidism due to increased turnover. In thyroid cancer with remnant ablation, effective half-life may be longer (up to 8 days) due to reduced clearance.
Terminal elimination half-life: 13-17 hours; clinically, effective half-life for brain SPECT imaging is 6-9 hours due to redistribution.
Primarily renal; approximately 90% excreted in urine within 72 hours, with the remainder eliminated via feces (biliary-fecal route, <10% in bile).
Renal: >90% as unchanged drug within 24 hours; biliary/fecal: <5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical